This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Psychiatry  • Depression  • Statistics and Research Methods  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Moving Beyond Placebo-Controlled Trials

David Knopman, MD; Jeffrey Kahn, PhD, MPH; Steven Miles, MD

Arch Neurol. 1998;55:1425-1429.

The design of clinical trials must evolve as new therapies become available. The demonstrated efficacy and clinical use of donepezil and vitamin E for Alzheimer disease (AD) has shifted the options for AD research design. There is now a compelling case for alternatives to trials that include a treatment arm with no active therapy (ie, a placebo control). With an existing therapy, such as donepezil or vitamin E, new drugs that are clearly superior to those drugs should be sought. Combination therapy is a likely strategy for the future, implying that clinical trials, if possible, should replicate actual practice. The long duration of future AD trials also will make placebo-controlled trials more difficult to justify and more difficult to recruit for. Add-on or active-control designs represent the alternative approaches. We believe that definitive clinical trials of new AD drugs that use one or the other of these designs would be more likely to bring about therapeutic advances than would comparisons with inactive treatments. Our argument is not a general rejection of placebo-control designs. Our recommendations apply only to the circumstances in which the field of AD drug therapy now finds itself.

From the Department of Neurology (Dr Knopman) and the Center for Bioethics (Drs Kahn and Miles), University of Minnesota, Minneapolis. Dr Knopman has served as a paid consultant to Parke-Davis Pharmaceutical Research Division, Ann Arbor, Mich; Athena Neurosciences Inc, South San Francisco, Calif; Bayer Corp, West Haven, Conn; Eisai/Pfizer Inc, New York, NY; Novartis Pharmaceuticals Corp, East Hanover, NJ; and Wyeth-Ayerst Laboratories, Philadelphia, Pa. He is currently conducting clinical trials with Bayer, Sigma-Tau Pharmaceuticals Inc, Gaithersburg, Md, and Forest Pharmaceuticals Inc, Maryland Heights, Mo. Drs Kahn and Miles have had no contacts with the pharmaceutical industry with regard to Alzheimer disease therapies.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

New Treatments in Alzheimer Disease and the Continued Need for Placebo-Controlled Trials
Martin R. Farlow
Arch Neurol. 1998;55(11):1396-1398.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Olazaran et al.
Neurology 2004;63:2348-2353.
ABSTRACT | FULL TEXT  

DHEA for Alzheimer's disease: A modest showing by a superhormone
Knopman and Henderson
Neurology 2003;60:1060-1061.
FULL TEXT  

Alternative Neurology
Rosenberg
Arch Neurol 1998;55:1394-1395.
FULL TEXT  

New Treatments in Alzheimer Disease and the Continued Need for Placebo-Controlled Trials
Farlow
Arch Neurol 1998;55:1396-1398.
FULL TEXT